{"id":62944,"date":"2026-04-12T22:28:30","date_gmt":"2026-04-12T14:28:30","guid":{"rendered":"https:\/\/flcube.com\/?p=62944"},"modified":"2026-04-12T22:28:30","modified_gmt":"2026-04-12T14:28:30","slug":"duality-biologics-files-nmpa-market-approval-for-db-1303-her2-adc-phase-iii-study-beats-t-dm1-in-metastatic-breast-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62944","title":{"rendered":"Duality Biologics Files NMPA Market Approval for DB-1303 HER2 ADC \u2013 Phase III Study Beats T-DM1 in Metastatic Breast Cancer"},"content":{"rendered":"\n<p><strong>Duality Biologics<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/9606:HKG\">HKG:\u202f9606<\/a>), a <strong>US\u2011China dual\u2011headquartered antibody\u2011drug conjugate (ADC) developer<\/strong>, announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has <strong>accepted for review<\/strong> its <strong>market approval filing<\/strong> for <strong>DB-1303<\/strong> (partner <strong>BioNTech SE<\/strong> code: <strong>BNT323<\/strong>), a <strong>HER2\u2011targeted ADC<\/strong> for metastatic breast cancer.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Filing Status<\/strong><\/td><td>Market approval application <strong>accepted for review<\/strong><\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>DB-1303 \/ BNT323 (HER2\u2011targeted ADC)<\/td><\/tr><tr><td><strong>Technology Platform<\/strong><\/td><td><strong>DITAC<\/strong> (Duality Immune Toxin Antibody Conjugate) \u2013 proprietary<\/td><\/tr><tr><td><strong>Partner<\/strong><\/td><td>BioNTech SE (global rights ex\u2011Greater China)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-phase-iii-clinical-evidence\">Phase III Clinical Evidence<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study<\/th><th>DB-1303-O-3001<\/th><\/tr><\/thead><tbody><tr><td><strong>Design<\/strong><\/td><td>Pivotal Phase III, randomized, T\u2011DM1 controlled<\/td><\/tr><tr><td><strong>Population<\/strong><\/td><td>HER2\u2011positive unresectable\/metastatic breast cancer; prior trastuzumab + taxane exposure<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td><strong>Progression\u2011free survival (PFS)<\/strong> \u2013 IDMC\u2011assessed<\/td><\/tr><tr><td><strong>Outcome<\/strong><\/td><td><strong>Statistically significant and clinically meaningful PFS improvement<\/strong> vs. T\u2011DM1<\/td><\/tr><tr><td><strong>Safety<\/strong><\/td><td>Favorable tolerability profile<\/td><\/tr><tr><td><strong>Analysis<\/strong><\/td><td>Prespecified interim analysis<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context\">Strategic Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Duality Biologics:<\/strong> Retains <strong>Greater China commercial rights<\/strong>; NMPA filing represents <strong>first major regulatory submission<\/strong> from proprietary DITAC platform<\/li>\n\n\n\n<li><strong>BioNTech Partnership:<\/strong> Global collaboration leverages BioNTech&#8217;s <strong>mRNA\/ oncology infrastructure<\/strong> for ex\u2011China development; potential <strong>US\/EU BLA submissions 2026\u20112027<\/strong><\/li>\n\n\n\n<li><strong>DITAC Platform:<\/strong> Proprietary ADC technology enabling <strong>optimized payload\u2011linker chemistry<\/strong> and <strong>bystander killing effect<\/strong> for heterogeneous HER2 expression<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-outlook\">Market Context &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HER2+ Breast Cancer Market:<\/strong> China represents <strong>~45,000 annual new metastatic cases<\/strong>; HER2\u2011targeted therapies market <strong>US$2\u20113\u202fbillion<\/strong> domestically<\/li>\n\n\n\n<li><strong>T\u2011DM1 Positioning:<\/strong> Current 2L standard\u2011of\u2011care; DB-1303 <strong>head\u2011to\u2011head superiority<\/strong> supports <strong>premium pricing and rapid formulary adoption<\/strong><\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong><\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Asset<\/th><th>Company<\/th><th>Mechanism<\/th><th>China Status<\/th><\/tr><\/thead><tbody><tr><td>T\u2011DM1 (Kadcyla)<\/td><td>Roche<\/td><td>ADC<\/td><td>Marketed<\/td><\/tr><tr><td>T\u2011DXd (Enhertu)<\/td><td>Daiichi\/AZ<\/td><td>ADC<\/td><td>Marketed<\/td><\/tr><tr><td><strong>DB-1303<\/strong><\/td><td><strong>Duality\/BioNTech<\/strong><\/td><td><strong>ADC (DITAC)<\/strong><\/td><td><strong>NMPA review<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Forecast:<\/strong> Peak China sales projected at <strong>RMB 1.5\u20112.5\u202fbillion<\/strong> (US$210\u2011350\u202fmillion) by 2030, assuming 2027 approval and 20\u201130% 2L+ HER2+ mBC market share<\/li>\n\n\n\n<li><strong>Platform Expansion:<\/strong> DITAC pipeline includes <strong>DB-1310 (B7H3 ADC)<\/strong>, <strong>DB-1305 (TROP2 ADC)<\/strong>; validated DB-1303 data de\u2011risks follow\u2011on assets<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory approval timelines, commercial projections, and competitive positioning for DB-1303. Actual results may differ due to risks including NMPA review delays, reimbursement negotiations, T\u2011DXd competition, and manufacturing scale\u2011up challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026040901795_c-1.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026040901795_c.\"><\/object><a id=\"wp-block-file--media-7ecc59b1-7afb-4f7d-b9b8-9f0b3f35f606\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026040901795_c-1.pdf\">2026040901795_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026040901795_c-1.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-7ecc59b1-7afb-4f7d-b9b8-9f0b3f35f606\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Duality Biologics (HKG:\u202f9606), a US\u2011China dual\u2011headquartered antibody\u2011drug conjugate (ADC) developer, announced that the National Medical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,16,232,3974,38],"class_list":["post-62944","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-cancer","tag-duality-biologics","tag-hkg-9606","tag-market-approval-filings"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Duality Biologics Files NMPA Market Approval for DB-1303 HER2 ADC \u2013 Phase III Study Beats T-DM1 in Metastatic Breast Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Duality Biologics (HKG:\u202f9606), a US\u2011China dual\u2011headquartered antibody\u2011drug conjugate (ADC) developer, announced that the National Medical Products Administration (NMPA) has accepted for review its market approval filing for DB-1303 (partner BioNTech SE code: BNT323), a HER2\u2011targeted ADC for metastatic breast cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62944\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Duality Biologics Files NMPA Market Approval for DB-1303 HER2 ADC \u2013 Phase III Study Beats T-DM1 in Metastatic Breast Cancer\" \/>\n<meta property=\"og:description\" content=\"Duality Biologics (HKG:\u202f9606), a US\u2011China dual\u2011headquartered antibody\u2011drug conjugate (ADC) developer, announced that the National Medical Products Administration (NMPA) has accepted for review its market approval filing for DB-1303 (partner BioNTech SE code: BNT323), a HER2\u2011targeted ADC for metastatic breast cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62944\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-12T14:28:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62944#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62944\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Duality Biologics Files NMPA Market Approval for DB-1303 HER2 ADC \u2013 Phase III Study Beats T-DM1 in Metastatic Breast Cancer\",\"datePublished\":\"2026-04-12T14:28:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62944\"},\"wordCount\":366,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Cancer\",\"Duality Biologics\",\"HKG: 9606\",\"Market approval filings\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62944#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62944\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62944\",\"name\":\"Duality Biologics Files NMPA Market Approval for DB-1303 HER2 ADC \u2013 Phase III Study Beats T-DM1 in Metastatic Breast Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-12T14:28:30+00:00\",\"description\":\"Duality Biologics (HKG:\u202f9606), a US\u2011China dual\u2011headquartered antibody\u2011drug conjugate (ADC) developer, announced that the National Medical Products Administration (NMPA) has accepted for review its market approval filing for DB-1303 (partner BioNTech SE code: BNT323), a HER2\u2011targeted ADC for metastatic breast cancer.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62944#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62944\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62944#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Duality Biologics Files NMPA Market Approval for DB-1303 HER2 ADC \u2013 Phase III Study Beats T-DM1 in Metastatic Breast Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Duality Biologics Files NMPA Market Approval for DB-1303 HER2 ADC \u2013 Phase III Study Beats T-DM1 in Metastatic Breast Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Duality Biologics (HKG:\u202f9606), a US\u2011China dual\u2011headquartered antibody\u2011drug conjugate (ADC) developer, announced that the National Medical Products Administration (NMPA) has accepted for review its market approval filing for DB-1303 (partner BioNTech SE code: BNT323), a HER2\u2011targeted ADC for metastatic breast cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62944","og_locale":"en_US","og_type":"article","og_title":"Duality Biologics Files NMPA Market Approval for DB-1303 HER2 ADC \u2013 Phase III Study Beats T-DM1 in Metastatic Breast Cancer","og_description":"Duality Biologics (HKG:\u202f9606), a US\u2011China dual\u2011headquartered antibody\u2011drug conjugate (ADC) developer, announced that the National Medical Products Administration (NMPA) has accepted for review its market approval filing for DB-1303 (partner BioNTech SE code: BNT323), a HER2\u2011targeted ADC for metastatic breast cancer.","og_url":"https:\/\/flcube.com\/?p=62944","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-12T14:28:30+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62944#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62944"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Duality Biologics Files NMPA Market Approval for DB-1303 HER2 ADC \u2013 Phase III Study Beats T-DM1 in Metastatic Breast Cancer","datePublished":"2026-04-12T14:28:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62944"},"wordCount":366,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Cancer","Duality Biologics","HKG: 9606","Market approval filings"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62944#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62944","url":"https:\/\/flcube.com\/?p=62944","name":"Duality Biologics Files NMPA Market Approval for DB-1303 HER2 ADC \u2013 Phase III Study Beats T-DM1 in Metastatic Breast Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-12T14:28:30+00:00","description":"Duality Biologics (HKG:\u202f9606), a US\u2011China dual\u2011headquartered antibody\u2011drug conjugate (ADC) developer, announced that the National Medical Products Administration (NMPA) has accepted for review its market approval filing for DB-1303 (partner BioNTech SE code: BNT323), a HER2\u2011targeted ADC for metastatic breast cancer.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62944#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62944"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62944#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Duality Biologics Files NMPA Market Approval for DB-1303 HER2 ADC \u2013 Phase III Study Beats T-DM1 in Metastatic Breast Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62944","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62944"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62944\/revisions"}],"predecessor-version":[{"id":62946,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62944\/revisions\/62946"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62944"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62944"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62944"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}